Trombosit fonksiyon testlerini etkileyen faktörler

Şermin Tetik; Koray Ak; Kevser Yardımcı

Trombosit fonksiyon testlerini etkileyen faktörler

Year 2012, Volume: 34 Issue: 1, 123 - 127, 27.03.2012

Şermin Tetik Koray Ak Kevser Yardımcı

Abstract

Özet

Fizyolojik koşullarda sirkülasyondaki trombositlerin görevi bir damar hasarı oluştuğunda kan kaybını engellemektir. Subendotele trombosit-trombosit adezyonunu sağlayan ve hasara uğramış damar duvarında geçici olarak “trombosit tıkacı” oluşturan bu sistem ateroskleroz veya arterial tromboz gibi patolojik şartlarda ise lokal iskemiye veya aterosklerotik lezyona sebep olmaktadır. Klinik çalışmalarda temel alınan trombosit fonksiyon testleri trombositlerin agonistlere olan duyarlığı ve oluşan trombosit cevabındaki spesifiklik açısından öneme sahiptir. Bu çalışmada trombosit fonksiyon testlerini etkileyen parametreler, yapılmış çalışmalarla karşılaştırmalı olarak incelenmiştir.

Anahtar sözcükler: Trombosit, trombosit fonksiyonu, agonist

Abstract

Under physiological conditions the function of thrombocytes in circulation is to inhibit the blood loss upon endothelial damage. This system which establishes thrombocyte adhesion to sub-endothelium and forms temporary thrombocyte plug at the damaged endothelial wall causes ischemia or atherosclerotic lesions under pathological conditions such as atherosclerosis and arterial thrombosis. The thrombocyte function tests which are taken as basis for clinical studies, are important in determining the sensitivity of thrombocytes to agonists and specificity of thrombocyte answer. In this study, the parameters affecting thrombocyte function tests are examined comparatively with literature results.

Keywords: Thrombocyte, thrombocyte function, agonist

Keywords

References

Chan ER, Lavender H, Li G, Haviernik P, Bunting KD, Adams MD. An ENU- induced recessive mutation in Mpl leads to thrombocytopenia with overdominance. Exp Hematology 2009; 37: 276-84.
Youssefian T, Drouin A, Massé JM, J Guichard J, Cramer EM. Host defense role of platelets: engulfment of HIV and Staphylococcus aureus occurs in a specific subcellular compartment and is enhanced by platelet activation. Blood 2002; 99: 4021-9.
Battinelli E, Willoughby SR, Foxall T, Valeri CR, Loscalzo J. Induction of platelet formation from megakaryocytoid cells by nitric oxide. Proc Natl Acad Sci USA 2001; 98: 14458-63.
Bendayan M, Rasio EA. Evidence of a tubular system for transendothelial transport in arterial capillaries of the rete mirabile. J Histochem Cytochem 1997; 45: 1365-78.
Anitua E, Andia I, Ardanza B, Nurden P, Nurden AT. Autologous platelets as a source of proteins for healing and tissue regeneration. Thromb Haemost 2004; 91: 4-15.
Mannaioni PF, Di Bello MG, Masini E. Platelets and inflammation: Role of platelet-derived growth factor, adhesion molecules and histamine. Inflamm Res 1997; 46: 4-18.
Willoughby S, Holmes A, Loscalzo J. Platelets and cardiovascular disease. Eur J Cardiovasc Nurs 2002; 1: 273-88.
Varga-Szabo D, Pleines I, Nieswandt B. Cell adhesion mechanisms in platelets. Arterioscler Thromb Vasc Biol 2008; 28: 403-12.
Morrell Craig N, Maggirwar SB. Recently recognized platelet agonists. Curr Opin Hematol. 2011; 18: 309-14.
Davi G, Catalano I, Averna M, Notarbartolo A, Strano A, Ciabattoni G, Patrono C. Thromboxane biosynthesis and platelet function in type II diabetes mellitus. N Engl J Med 1990; 322: 1769-74.
Schneider DJ, Tracy PB, Mann KG, Sobel BE. Differential effects of anticoagulants on the activation of platelets ex vivo. Circulation 1997; 96: 2877- 83.
Tardiff BE, Jennings LK, Harrington RA, Gretler D, Potthoff RF, Vorchheimer DA, Eisenberg PR, Lincoff AM, Labinaz M, Joseph DM, McDougal MF, Kleiman NS; PERIGEE Investigators. Pharmacodynamics and pharmacokinetics of eptifibatide in patients with acute coronary syndromes: prospective analysis from PURSUIT. Circulation 2001; 104: 399-405.
Labarthe B, Theroux P, Angioi M, Ghitescu M. Matching the evaluation of the clinical efficacy of clopidogrel to platelet function tests relevant to the biological properties of the drug. J Am Coll Cardiol 2005; 46: 638-45.
Gurbel PA, Bliden KP, Etherington A, Tantry US. Assessment of clopidogrel responsiveness: measurements of maximum platelet aggregation, final platelet aggregation and their correlation with vasodilator-stimulated phosphoprotein in resistant patients. Thromb Res 2007; 121: 107-15.
Sanioglu S, Tetik S, Sokullu O, Deniz H, Aydemir N, Yılmaz M, Arslan IY, Bilgen F. Aspirin resistance after CABG. Thorac Cardiovasc Surg 2009; 57: 281- 5.
Özsavcı D, Şener A, Oba R, Yanıkkaya-Demirel G, Uras F, Yardımcı KT. New in vitro effects of clopidogrel on platelets in hyperlipidemic and healthy subjects. Turk J Hemotol 2010; 27: 99-108.
Tetik Ş, Ak K, İşbir S, Ekşioğlu-Demiralp E, Arsan S, Iqbal O, Yardımcı T. Clopidogrel provides significantly greater inhibition of platelet activity than aspirin when combined with atorvastatin after coronary artery bypass grafting: a prospective randomized study. Thromb Hemos Clin Appl 2010; 16: 189-98.
de Padua Mansur A, Caramelli B, Vianna CB, Chamone D, Ramires JA. Smoking and lipoprotein abnormalities on platelet aggregation in coronary heart disease. Int J Cardiol 1997; 62: 151-4.
Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B, Graham I. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 1991; 324: 1149-55.
Brattstrom LE, Hardebo JE, Hultberg BL. Moderate homocysteinemia-a possible risk factor for arteriosclerotic cerebrovascular disease. Stroke 1984; 15: 1012-6.
Stamler JS, Osborne JA, Jaraki O, Rabbani LE, Mullins M, Singel D, Loscalzo J. Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest 1993; 91: 308-18.
Puddu PE, Schiariti M Bugiardini R. Glycoprotein IIb/IIIa Antagonists in Acute Coronary Syndromes Undergoing PCI: A Long Way to Select Optimal Agent and Route. ISRN Vascular Medicine2011 ID 141430, p 9
Tetik Ş, Ak K. Kardiyovasküler hastalıklarda trombosit fonksiyon testleri: patofizyolojiden klinik yaklaşıma. Cumhuriyet tıp dergisi 2010; 32: 264-74.
Nurden A, Nurden P. Advances in our understanding of the molecular basis of disorders of platelet function. J Thromb Haemost 2011; 9 Suppl 1: 76-91.